Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Inclusion Criteria:

* PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:

  * Age: 50 or older, plus at least one of the following:

    * Mutation unknown or absent:

      * 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
      * OR 2+ affected first degree relatives \[(FDR), defined as blood related parents, siblings, or children\]
    * Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:

      * CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
    * OR 1+ or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:

      * ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
* HIGH-RISK OR WORRISOME PANCREATIC CYSTS:

  * 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria

    * High risk stigmata:

      * Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
      * Enhancing mural nodule ≥ 5 mm
      * Main pancreatic duct ≥ 10 mm
    * Worrisome features:

      * Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm
      * Cyst ≥ 3 cm
      * Enhancing mural nodule \< 5 mm
      * Thickened/Enhancing cyst wall
      * Main duct size 5-9 mm
      * Pancreatitis
      * Lymphadenopathy
      * Increased CA 19-9
      * Cyst growth rate ≥ 5 mm /2 years

Exclusion Criteria:

* Is unable to provide informed consent
* Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
* Current or prior history of PDAC or total pancreatectomy
* Is currently a prison inmate
* Is not able to speak or read English